Restrictions on Transferring Materials. Abgenix recognizes that the biological and biochemical materials which are part of Pfizer Technology or Joint Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for five (5) years thereafter, Abgenix agrees not to transfer such materials to any third party, unless prior written, consent for any such transfer is obtained from Pfizer.
Restrictions on Transferring Materials. Pfizer and Peptide recognise that the biological, synthetic chemical and biochemical materials which are part of Pfizer Technology, Peptide Technology or Joint Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for seven (7) years thereafter, subject to the license rights granted in Section 5.3, Peptide and Pfizer agree not to transfer such materials of the other party or joint materials to any third party, unless prior written consent for any such transfer is obtained from the other party.
Restrictions on Transferring Materials. Subject to the grant of license to Pfizer in Section 5.2, Pfizer and ArQule recognize that the synthetic chemical materials, including, but not limited to, monomers, chemical components, intermediates, and reagents which are part of ArQule Technology or Pfizer Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for [*] years thereafter, ArQule and Pfizer agree not to ------------------ *Confidential treatment has been requested for the marked portion. transfer such materials received from the other party to any third party, unless prior written consent for any such transfer is obtained from the other party. For the purposes of this Section 4.5, ArQule employees outside of the Production Facility shall be viewed as third parties with respect to Pfizer Technology (i.e. materials within Pfizer Technology shall not be transferred to ArQule outside the Production Facility).
Restrictions on Transferring Materials. Pfizer and Myco recognize that the biological, synthetic chemical and biochemical materials which are part of Pfizer Non-Program Technology, Pfizer Program Technology, Myco Program Technology, Myco Non-Program Technology or Joint Technology, (collectively, the "Materials") represent valuable commercial assets. Therefore, throughout the Contract Period and the Option Period under the License Agreement and for [ ] years thereafter, Myco and Pfizer agree not to transfer such materials which are part of Joint Technology or the other party's Technology to any third party, unless prior written consent for any such transfer is obtained from the other party, except as expressly permitted in this Agreement or the License Agreement. Furthermore, throughout the Contract Period and the Option Period under the License Agreement Myco agrees not to transfer such materials which are part of the Myco Non-Program Technology or Myco Program Technology to any third party for use in the Area.
Restrictions on Transferring Materials. Pfizer and Isis recognize that the biological, synthetic chemical and biochemical materials which are part of [***], Isis Technology, Isis Know-how, [***], Isis Licensed Technology, Program Technology, or Program Know-how represent commercial assets. Therefore, throughout the Contract Period and for [***] thereafter, Isis and Pfizer agree not to transfer materials of the other party to any third party except for agents, unless prior written consent for any such transfer is obtained from the other party. Isis and Pfizer each represent that any employees, Affiliates, agents and any consultants to whom materials of the other party are transferred are bound by agreement to use such materials only as expressly permitted by this Agreement, and by assignment obligations in favor of the transferring party as are appropriate to effect the ownership provisions of Section 5.1.
Restrictions on Transferring Materials. Tanabe and OSI recognize that the Materials which are part of OSI Technology, Tanabe Technology or Improvements represent valuable commercial assets. Therefore, throughout the Contract Period and for ** thereafter (unless the other party consents thereto, which consent shall not be unreasonably withheld or delayed), each of OSI and Tanabe agrees not to transfer to any Third Party any such Materials which constitute Technology owned solely by the other party to this Agreement; provided, however, that OSI may transfer any such Materials to Vanderbilt to the extent necessary in order for OSI to perform its obligations under this Agreement and to the extent Vanderbilt is obligated at least under the same degree of confidentiality and non-use obligation as OSI is obligated hereunder. Additionally, throughout the Contract Period and for ** thereafter, OSI and Tanabe agree not to transfer to any Third Party any Materials which are part of the Improvements (except that OSI may transfer any such Materials to Vanderbilt to ------------------- ** This portion has been redacted pursuant to a request for confidential treatment.
Restrictions on Transferring Materials. Becton and OSI recognize that the biological, chemical and biochemical materials which are part of OSI Technology or Becton Technology represent valuable commercial assets. Accordingly, except as otherwise permitted by Section 12.6 hereof, throughout the term hereof and for five (5) years thereafter, OSI and Becton agree not to transfer to any Third Person any such material which 18 20 constitutes Technology owned solely by the other party. Additionally, except as otherwise permitted by Section 12.6 hereof, throughout the term hereof and for six (6) months thereafter, OSI and Becton agree not to transfer to any Third Person any biological, chemical or biochemical materials which comprise, consist of or are useful in the manufacture of any Product, unless prior consent for any such transfer is obtained from the other party, which consent may not be unreasonably withheld and unless such Third Person agrees as a condition of any such transfer not to transfer the material further and to use the material for research purposes not directed toward the development of Diagnostic Products. The provisions of this Section 7.3 specifically do not apply to transfer to Pfizer Inc. pursuant to any agreements between OSI and Pfizer Inc. for purposes other than developing Diagnostic Products.
Restrictions on Transferring Materials. FRI and OSI recognize that the biological, chemical and biochemical materials which are part of the OSI Technology and FRI Technology represent valuable commercial assets. Accordingly, nothing containing herein shall be construed to permit either party to transfer to any third person (including Bayer) any such material which constitutes Technology owned by the other party. Additionally, subject to FRI's rights as set forth herein, throughout the term hereof and thereafter, FRI agrees not to transfer to any third person any biological, chemical or biochemical materials which are part of OSI Technology and which comprise, consist of or are useful in the manufacture of any Licensed Product or OSI Product, unless prior consent for any such transfer is obtained from OSI.
Restrictions on Transferring Materials. Each Party recognizes that the biological and biochemical materials which are part of Pfizer Technology, Medarex Technology or Program Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for five (5) years thereafter, each Party agrees that it will not transfer such materials of the other Party to any third party, unless prior written consent for any such transfer is obtained from such other Party.
Restrictions on Transferring Materials. Pfizer and Gensia recognize that the biological, synthetic chemical and biochemical materials which are part of Pfizer Technology, Gensia Technology or Joint Technology, represent valuable commercial assets. Therefore, [CONFIDENTIAL TREATMENT REQUESTED], except as may be required in a contract described in Section 1.9(b) or 1.11(b), Gensia and Pfizer agree not to transfer such joint materials or materials of the other party to any third party, unless prior written consent for any such transfer is obtained from the other party.
